Cerenome Inc. (CNSY)
NASDAQ: CNSYHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
CNSY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $13.59M
- EPS (TTM)
- -$3.36
- Dividend yield
- None
- 52-week range
- 1.49 – 19.00
- Day range
- 1.60 – 1.80
- Volume / Avg
- 122.18K / 121.12K
- Beta
- —
- Shares outstanding
- 7.59M
- Next earnings
- Oct 29, 2026
52-week range
CNSY stock today
On Oct 8, CNSY ended the session at $1.79, adding $0.155 (9.48%), versus the S&P 500's 0.47% decline. Shares are 90.6% below their 52-week high of $19.00 and 20.1% above the 52-week low of $1.49, near the bottom of the past year's range. CNSY is down 86.0% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 90.5%.
Cerenome has posted a net loss over the last twelve months (EPS of -$3.36), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 29; analysts expect EPS of -$0.98.
Summary generated from market data by MetaCap's automated system. Methodology
About Cerenome
Company profileCerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Marc H. Hedrick M.B.A., M.D.
- Headquarters
- Houston, TX
- Employees
- 28
- Website
- cerenome.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$27.75+1450.28%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $-0.98
CNSY news
All CNSY newsCerenome peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INABIN8bio Inc. | 1.38 | -1.43% | $13.60M | vs CNSY |
| KPTIKaryopharm Therapeutics Inc. | 0.60 | -6.98% | $13.61M | vs CNSY |
| NIKINiki BioSolutions Inc. | 4.32 | -7.10% | $13.47M | vs CNSY |
| CTXRCitius Pharmaceuticals Inc. | 0.4887 | -2.47% | $13.42M | vs CNSY |
| CLRBCellectar Biosciences Inc. | 1.40 | -7.28% | $13.23M | vs CNSY |
| TPSTTempest Therapeutics Inc. | 0.77 | -2.70% | $13.01M | vs CNSY |
| LSTALisata Therapeutics Inc. | 1.20 | +2.56% | $12.96M | vs CNSY |
| HINDVyome Holdings Inc. | 2.03 | -0.49% | $14.25M | vs CNSY |
Indexes, lists and sector
Appears in lists
Cerenome stock FAQ
What is Cerenome's stock price today?
CNSY last traded at $1.79 as of Oct 8, 4:00 PM EDT, up 9.48% on the day. Prices are delayed at least 15 minutes.
Does Cerenome pay a dividend?
No. Cerenome does not currently pay a regular cash dividend.
When is Cerenome's next earnings date?
Cerenome is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $-0.98.
Who is Cerenome's CEO?
Dr. Marc H. Hedrick M.B.A., M.D. is the chief executive officer of Cerenome Inc., which has about 28 employees.
Has CNSY ever split its stock?
Yes. The most recent CNSY stock split was a 1-for-25 split on Apr 2, 2026, one of 5 splits on record.
What is the CNSY 52-week high?
The 52-week high for CNSY is $19.00 and the 52-week low is $1.49. The stock is currently 90.6% below its high.